Tempus AI, Inc. (TEM) Quick Ratio (Acid-Test): 3.00
Is Tempus AI, Inc.’s quick ratio (acid-test) high or low?
Tempus AI, Inc.'s quick ratio (acid-test) of 3.00 is in line with its 5-year average of 3.05, around the middle of its 5-year range (1.38–6.04).
As of Friday, June 12, 2026. 16.28% above its 12-month average of 2.58.
TEM Quick Ratio (Acid-Test) Chart
TEM Average Quick Ratio (Acid-Test) Chart
TEM Current vs Average Quick Ratio (Acid-Test) Chart
TEM Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
3.00
QUICK RATIO (ACID-TEST) AVG TTM
2.58
QUICK RATIO (ACID-TEST) AVG 3Y
2.23
QUICK RATIO (ACID-TEST) AVG 5Y
3.05
QUICK RATIO (ACID-TEST) AVG 10Y
3.49
QUICK RATIO (ACID-TEST) AVG 15Y
3.49
QUICK RATIO (ACID-TEST) AVG 20Y
3.49
CURRENT VS TTM AVG
+16.28%
CURRENT VS 3Y AVG
+34.38%
CURRENT VS 5Y AVG
-1.59%
CURRENT VS 10Y AVG
-14.00%
CURRENT VS 15Y AVG
-14.00%
CURRENT VS 20Y AVG
-14.00%
TEM Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | 3.00 | 2.58 | 2.23 | 3.05 |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 1.02 | 1.07 | 1.10 | 1.11 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 4.19 | 4.52 | 4.42 | 3.69 |
| Baxter International Inc. (BAX) | $10.58B | 1.56 | 1.31 | 1.23 | 1.40 |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | 1.61 | 1.56 | 2.48 | 3.39 |
| Align Technology, Inc. (ALGN) | $12.64B | 1.24 | 1.17 | 1.11 | 1.16 |
| Solventum Corporation (SOLV) | $13.72B | 0.89 | 0.86 | 0.93 | 0.94 |
| Hologic, Inc. (HOLX) | $16.97B | 3.06 | 3.04 | 3.12 | 2.66 |
| 23andMe Holding Co. (ME) | $15.31M | 0.70 | 1.29 | 2.30 | 2.23 |
| Moderna, Inc. (MRNA) | $19.70B | 3.22 | 3.42 | 3.19 | 2.63 |
Liquidity Comparison
Quick Ratio
3.00
Excludes inventory
Current Ratio
3.13
Includes inventory
Tempus AI, Inc. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Tempus AI, Inc. (TEM)?
- The quick ratio (acid-test) for TEM stock is 3.00.
- Is Tempus AI, Inc.'s quick ratio (acid-test) high or low?
- Tempus AI, Inc.'s quick ratio (acid-test) of 3.00 is in line with its 5-year average of 3.05, around the middle of its 5-year range (1.38–6.04).
- What is the TTM average quick ratio (acid-test) for Tempus AI, Inc. (TEM)?
- The TTM average quick ratio (acid-test) for TEM stock is 2.58.
- What is the 3Y average quick ratio (acid-test) for Tempus AI, Inc. (TEM)?
- The 3Y average quick ratio (acid-test) for TEM stock is 2.23.
- What is the 5Y average quick ratio (acid-test) for Tempus AI, Inc. (TEM)?
- The 5Y average quick ratio (acid-test) for TEM stock is 3.05.
- What is the 10Y average quick ratio (acid-test) for Tempus AI, Inc. (TEM)?
- The 10Y average quick ratio (acid-test) for TEM stock is 3.49.
- What is the 15Y average quick ratio (acid-test) for Tempus AI, Inc. (TEM)?
- The 15Y average quick ratio (acid-test) for TEM stock is 3.49.
- What is the 20Y average quick ratio (acid-test) for Tempus AI, Inc. (TEM)?
- The 20Y average quick ratio (acid-test) for TEM stock is 3.49.
Tempus AI, Inc. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 3.00 |
| 2024-12-31 | 2.16 |
| 2023-12-31 | 1.38 |
| 2022-12-31 | 2.39 |
| 2021-12-31 | 3.32 |
| 2020-12-31 | 6.04 |
| 2019-12-31 | 6.13 |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky